NCT01048983 is a Phase 1, PHASE2 clinical trial of Armodafinil in Non Small Cell Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01048983?

NCT01048983 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01048983?

Interventions in NCT01048983: Armodafinil, Bupropion, Minocycline, Curcumin, Telephone Questionnaire.

What condition does NCT01048983 study?

NCT01048983 studies Non Small Cell Lung Cancer.

Is NCT01048983 still recruiting?

NCT01048983 is currently withdrawn. Last updated 5 March 2015.

Last reviewed 2015-03-05 · How we verify

NCT01048983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

Withdrawn Phase 1, PHASE2 Last updated 5 March 2015

What this trial tests

Phase 1, PHASE2 trial testing Armodafinil in Non Small Cell Lung Cancer. Withdrawn.

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	triple
Primary purpose	supportive care

Drugs / interventions tested

Armodafinil (ARMODAFINIL) — full drug profile →
Bupropion (bupropion) — full drug profile →
Minocycline (MINOCYCLINE) — full drug profile →
Curcumin (CURCUMIN) — full drug profile →
Telephone Questionnaire

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 65, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Manganese superoxide dismutase in cancer prevention.
Robbins D, Zhao Y. · · 2014 · cited 62× · PMID 23706068 · DOI 10.1089/ars.2013.5297
Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence.
Nizami ZN, Aburawi HE, Semlali A, Muhammad K, et al · · 2023 · cited 40× · PMID 37371889 · DOI 10.3390/antiox12061159
An Overview of the Enhanced Effects of Curcumin and Chemotherapeutic Agents in Combined Cancer Treatments.
Cacciola NA, Cuciniello R, Petillo GD, Piccioni M, et al · · 2023 · cited 26× · PMID 37628772 · DOI 10.3390/ijms241612587
Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations.
Tang C, Liu J, Yang C, Ma J, et al · · 2022 · cited 26× · PMID 36358986 · DOI 10.3390/biom12111636
Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
Park W, Han JH, Wei S, Yang ES, et al · · 2024 · cited 9× · PMID 38255882 · DOI 10.3390/ijms25020807
Bioactive components and delivery strategies of food-medicine homologous substances in lung cancer therapy: current advances and clinical translation.
Sun M, Zang D, Chen J. · · 2025 · PMID 41473195 · DOI 10.3389/fnut.2025.1696289

Verify or expand the search:

Other trials of Armodafinil

Trials testing the same drug.

NCT01330446 — Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer · Phase 1, PHASE2 · completed
NCT01256905 — Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies · NA · withdrawn
NCT01032200 — Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors · Phase 2 · completed
NCT01121536 — Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depressio · Phase 3 · terminated
NCT01096680 — Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss · Phase 2 · completed

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01048983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 5 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01048983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing